To read the full story, subscribe or sign in.

Gates Foundation, Wellcome Trust set up drug development accelerator targeting COVID-19

March 10, 2020

LONDON – The Gates Foundation and Wellcome Trust have joined forces with financial services specialist Mastercard in establishing a $125 million seed fund to accelerate development of drugs to treat COVID -19.

BioWorld Asia Deals and M&A

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for Jan. 27, 2022.

Novavax’s protein-based COVID-19 vaccine wins approval in South Korea

BioWorld

South Korea’s Ministry of Food and Drug Safety (MFDS) has greenlighted Novavax Inc.’s Nuvaxovid, making it the first protein-based COVID-19 vaccine to be approved...

Today's news in brief

BioWorld MedTech's briefs for Jan. 27.

Stryker acquires Vocera in $3B cash deal

BioWorld MedTech

Stryker Corp. reported that it signed a definitive merger agreement to acquire Vocera Communications Inc. for $2.97 billion in an all-cash transaction expected to...

Upgrade your daily dose of biopharma and medtech news

Gates Foundation, Wellcome Trust set up drug development accelerator targeting COVID-19